

18th January 2021

Methodological note for Valneva UK Transfer of Value Disclosure 2020.

Valneva UK is a travel vaccine company. Its fifth year of trading was 2020, within that year it marketed two Prescription Only Medicines, and one Consumer product.

To assist the company, Valneva UK contracted one nurse and one MD for the participation in an image video for the company. Valneva UK also sponsored two separate HCP education events for which another nurse and two additional MDs were contracted as speakers. Valneva UK also contracted the Chief Executive of the Encephalitis Society, a UK charity, to support awareness of this misunderstood condition. The Chief Executive of the Encephalitis Society received £840 as an honorarium for speaking at a Webinar on the topic of “COVID-19 Encephalitis” sponsored by Valneva, no reimbursement for travel expenses or accommodation were made in relation to this engagement. Additionally, Valneva US paid for travel and accommodation for the Chief Executive to the US amounting to £1287.55 to facilitate a meeting with representatives from Valneva US to discuss licensing of the Encephalitis Society’s Japanese Encephalitis patient videos for medical education purposes in the US.

To support medical education in the UK, Valneva UK supported the establishment of a diploma in travel medicine for health care professionals by the Faculty of Travel Medicine at the Royal College of Physicians and Surgeons of Glasgow with an educational grant (sponsorship amount £25000), which concludes all payments in 2020.

There were no further contracts undertaken in the calendar year 2020, all amounts given exclude VAT unless stated otherwise. All of the contractors were paid in pound sterling in England, none of the contractors exceeded VAT thresholds and all were left accountable for their own income tax.

An assessment was made as to the hourly charge of each contract to ensure that the charge was fair market value. Activities were assessed to ensure that contractor input was absolutely necessary for the success of each project. Activities where

contractor input was deemed necessary were notified in advance and the contractor could opt in or out of taking part in that activity or project.

Other transfers of value were made to several separate travel health organisations and pharmacies by Valneva UK in 2020. All transfers of value relate to the “Valneva in Partnership” joint working programme. These programmes assist pharmacies and existing travel clinics to offer a comprehensive travel service through marketing and educational support- support designed to ensure travellers seek appropriate travel health advice before travelling and that they have access to travel services when required. Details of the joint working agreements with each of the 3 organisations, [Avicenna, Lindsey and Gilmour, Greenlife Pharma], can be found here: <https://www.valnevauk.com/transparency/>

Valneva UK has no multi-year contracts for individual external contractors. There were no over-the-counter transfers of value or medical device transfers of value for 2020. There were no further contracts, donations, grants or sponsorships made to HCPs or HCOs in 2020.

Yours Faithfully,

A handwritten signature in black ink, appearing to be 'JC', written in a cursive style.

Christoph Jandl, PhD